ACHIEVE-1

Phase 3 clinical trial of orforglipron in type 2 diabetes, involving 559 participants over 40 weeks. Published in NEJM in June 2025, it showed an HbA1c reduction of 1.48 points with the 36 mg dose compared with 0.41 on placebo.

Institutional endorsement by Clínica Evolution

This entry is for information. Your case requires an individual medical assessment.